Cargando…

Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes

Detection of androgen receptor (AR) variant 7 (AR-V7) is emerging as a clinically important biomarker in castrate resistant prostate cancer (CRPC). Detection is possible from tumor tissue, which is often inaccessible in the advanced disease setting. With recent progress in detecting AR-V7 in circula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nimir, Mohammed, Ma, Yafeng, Jeffreys, Sarah A., Opperman, Thomas, Young, Francis, Khan, Tanzila, Ding, Pei, Chua, Wei, Balakrishnar, Bavanthi, Cooper, Adam, De Souza, Paul, Becker, Therese M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678978/ https://www.ncbi.nlm.nih.gov/pubmed/31288377 http://dx.doi.org/10.3390/cells8070688

Ejemplares similares

Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies
por: Ma, Yafeng, et al.
Publicado: (2016)

Choice of antibody is critical for specific and sensitive detection of androgen receptor splice variant-7 in circulating tumor cells
por: Khan, Tanzila, et al.
Publicado: (2022)

CTC-mRNA (AR-V7) Analysis from Blood Samples—Impact of Blood Collection Tube and Storage Time
por: Luk, Alison W. S., et al.
Publicado: (2017)

Biomarkers of Castrate Resistance in Prostate Cancer: Androgen Receptor Amplification and T877A Mutation Detection by Multiplex Droplet Digital PCR
por: Young, Francis P., et al.
Publicado: (2022)

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer
por: Sugiura, Masahiro, et al.
Publicado: (2020)

Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis
por: Khan, Tanzila, et al.
Publicado: (2022)

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients
por: Schlack, Katrin, et al.
Publicado: (2022)

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients
por: Cattrini, Carlo, et al.
Publicado: (2019)

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2020)

The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?
por: Khan, Tanzila, et al.
Publicado: (2020)

Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
por: Kallio, Heini M. L., et al.
Publicado: (2018)

Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer
por: Wüstmann, Neele, et al.
Publicado: (2023)

Selective degradation of AR-V7 to overcome castration resistance of prostate cancer
por: Liu, Yuan, et al.
Publicado: (2021)

Expression of Androgen Receptor Variant 7 (AR-V7) in Circulated Tumor Cells and Correlation with Drug Resistance of Prostate Cancer Cells
por: Wang, Shuaibin, et al.
Publicado: (2018)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer
por: Jones, Dominic, et al.
Publicado: (2017)

Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer
por: Lu, David, et al.
Publicado: (2020)

Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients
por: Lieb, Verena, et al.
Publicado: (2021)

AR splice variants in circulating tumor cells of patients with castration‐resistant prostate cancer: relation with outcome to cabazitaxel
por: Sieuwerts, Anieta M., et al.
Publicado: (2019)

Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
por: Bratic Hench, Ivana, et al.
Publicado: (2019)

Novel AR/AR-V7 and Mnk1/2 Degrader, VNPP433-3β: Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models
por: Thomas, Elizabeth, et al.
Publicado: (2022)

Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer
por: Qu, Yuanyuan, et al.
Publicado: (2015)

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
por: Luo, Jun
Publicado: (2016)

Single-Circulating Tumor Cell Whole Genome Amplification to Unravel Cancer Heterogeneity and Actionable Biomarkers
por: Khan, Tanzila, et al.
Publicado: (2022)

Huaier Extract Inhibits Prostate Cancer Growth via Targeting AR/AR-V7 Pathway
por: Liu, Zhengfang, et al.
Publicado: (2021)

Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications
por: Zhao, Pei, et al.
Publicado: (2019)

Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy
por: Liao, Yuning, et al.
Publicado: (2020)

Clinical utility of the nuclear-localized AR-V7 biomarker for treatment choice in metastatic castration-resistant prostate cancer
por: Vlaeminck-Guillem, Virginie
Publicado: (2020)

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer
por: Kim, Seaho, et al.
Publicado: (2022)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

AR-v7 protein expression is regulated by protein kinase and phosphatase
por: Li, Yinan, et al.
Publicado: (2015)

The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression
por: Tong, Dali
Publicado: (2021)

Circulating tumor cell gene expression and plasma AR gene copy number as biomarkers for castration-resistant prostate cancer patients treated with cabazitaxel
por: Gurioli, Giorgia, et al.
Publicado: (2022)

Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer
por: Khurana, Namrata, et al.
Publicado: (2017)

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance
por: Zhang, Boya, et al.
Publicado: (2021)

Peptides disrupting TM4SF3 interaction with AR or AR-V7 block prostate cancer cell proliferation
por: Khatiwada, Prabesh, et al.
Publicado: (2023)

Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo
por: Kwegyir-Afful, Andrew K., et al.
Publicado: (2015)

Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer
por: Kafka, Mona, et al.
Publicado: (2020)

Correction to: The role of JMJD6/U2AF65/AR-V7 axis in castration-resistant prostate cancer progression
por: Tong, Dali
Publicado: (2021)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
por: Sobhani, Navid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_40nd1s3ubgjsbev3h66d8hoikh